Shukra Pharmaceuticals Limited has achieved a significant milestone by securing a pan-India authorization from Wockhardt Limited, a leading global pharmaceutical company. The authorization, valid from September 9, 2025, until March 2026, empowers Shukra Pharmaceuticals to represent, distribute, and manage Wockhardt’s products across all ESIC/ESIS hospitals as well as all Defence Hospitals, AFMSD, and DGAFMS units throughout India.
Under this non-exclusive agreement, Shukra Pharmaceuticals is authorized to quote products on behalf of Wockhardt, collect order copies, raise invoices, and receive payments directly. The partnership covers a range of advanced anti-infective formulations, including EMROK® (Levonadifloxacin) and MIQNAF® (Nafithromycin), breakthrough antibiotics designed to tackle critical infections effectively.
This strategic distributorship significantly enhances Shukra Pharmaceuticals’ presence within institutional and government healthcare networks across the country. By aligning with Wockhardt, a globally recognized name in healthcare, Shukra Pharmaceuticals is positioned to expand its operational footprint, improve revenue visibility, and create long-term value for its shareholders.
The Board and Management of Shukra Pharmaceuticals Limited have expressed confidence that this partnership will have a positive and lasting impact on the company’s financial and operational performance, reinforcing its growth trajectory in India’s expanding healthcare and hospital infrastructure.
